{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:24:37Z","timestamp":1781889877217,"version":"3.54.5"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Southampton Experimental Medicine Centre","award":["C24563\/A25141"],"award-info":[{"award-number":["C24563\/A25141"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Metastatic uveal melanoma (UM) carries a poor prognosis; liver is the most frequent and often solitary site of recurrence. Available systemic treatments have not improved outcomes. Melphalan percutaneous hepatic perfusion (M\u2010PHP) allows selective intrahepatic delivery of high dose cytotoxic chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective analysis of outcomes data of UM patients receiving M\u2010PHP at two institutions was performed. Tumor response and toxicity were evaluated using RECIST 1.1 and Common Terminology Criteria for Adverse Events (CTCAE) v4.03, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 51 patients received 134 M\u2010PHP procedures (median of 2 M\u2010PHPs). 25 (49%) achieved a partial (<jats:italic>N<\/jats:italic>\u2009=\u200922, 43.1%) or complete hepatic response (<jats:italic>N<\/jats:italic>\u2009=\u20093, 5.9%). In 17 (33.3%) additional patients, the disease stabilized for at least 3 months, for a hepatic disease control rate of 82.4%. After median follow\u2010up of 367 days, median overall progression free (PFS) and hepatic progression free survival (hPFS) was 8.1 and 9.1 months, respectively and median overall survival was 15.3 months. There were no treatment related fatalities. Non\u2010hematologic grade 3\u20104 events were seen in 19 (37.5%) patients and were mainly coagulopathic (<jats:italic>N<\/jats:italic>\u2009=\u20098) and cardiovascular (<jats:italic>N<\/jats:italic>\u2009=\u20099).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>M\u2010PHP results in durable intrahepatic disease control and can form the basis for an integrated multimodality treatment approach in appropriately selected UM patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.24956","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T19:00:26Z","timestamp":1514487626000},"page":"1170-1178","source":"Crossref","is-referenced-by-count":79,"title":["Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease"],"prefix":"10.1002","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-3141","authenticated-orcid":false,"given":"Ioannis","family":"Karydis","sequence":"first","affiliation":[{"name":"Cancer Sciences Academic Unit University of Southampton Southampton United Kingdom"},{"name":"University Hospital Southampton Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-7973","authenticated-orcid":false,"given":"Alexandra","family":"Gangi","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Wheater","sequence":"additional","affiliation":[{"name":"University Hospital Southampton Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Radiology Moffitt Cancer Center Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Wilson","sequence":"additional","affiliation":[{"name":"University Hospital Southampton Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Radiology Moffitt Cancer Center Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Pearce","sequence":"additional","affiliation":[{"name":"University Hospital Southampton Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Takhar","sequence":"additional","affiliation":[{"name":"University Hospital Southampton Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[{"name":"University Hospital Southampton Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hardman","sequence":"additional","affiliation":[{"name":"Morsani School of Medicine University of South Florida Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Sileno","sequence":"additional","affiliation":[{"name":"Morsani School of Medicine University of South Florida Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Stedman","sequence":"additional","affiliation":[{"name":"University Hospital Southampton Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ottensmeier","sequence":"additional","affiliation":[{"name":"Cancer Sciences Academic Unit University of Southampton Southampton United Kingdom"},{"name":"University Hospital Southampton Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(91)32285-1"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931001)72:7<2219::AID-CNCR2820720725>3.0.CO;2-J"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.12.1639"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.9345"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/TACG.S69210"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309034"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2013.786839"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118564"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30258"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1143997"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.12.024"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28480"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23535"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000356"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.11.1836"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23551"},{"key":"e_1_2_8_19_1","first-page":"6343","article-title":"Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver","volume":"9","author":"Alexander HR","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23474"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.927"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4968-3"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.013"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3455"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.24956","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.24956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T21:05:00Z","timestamp":1695503100000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.24956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,28]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/jso.24956"],"URL":"https:\/\/doi.org\/10.1002\/jso.24956","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,28]]}}}